Id: acc1052
Group: 2sens
Protein: cdc25C
Gene Symbol: CDC25C
Protein Id: P30305
Protein Name: MPIP2_HUMAN
PTM: phosphorylation
Site: Ser216
Site Sequence: HPSSTHALAEWASRREAFAQR
Disease Category: Cancer
Disease: Prostate Cancer
Disease Subtype:
Disease Cellline: DU145
Disease Info:
Drug: gallic acid
Drug Info: "Gallic acid is a natural phenolic compound with antioxidant, anti-inflammatory, and potential anticancer properties, studied for its therapeutic effects in various preclinical models but not yet approved as a standalone drug."
Effect: modulate
Effect Info: "Gallic acid causes phosphorylation of cdc25A/cdc25C-cdc2 through ATM-Chk2 activation, leading to cell cycle arrest and inducing apoptosis in human prostate cancer DU145 cells."
Note:
Score: 4.0
Pubmed(PMID): 17172433
Sentence Index:
Sentence:

Sequence & Structure:

MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMHDLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLSSESSESSDAGLCMDSPSPMDPHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLRNITNSQAPDGRRKSEAGSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPDRKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKTLEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVTPPEEQQEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAFLLQTVDGKHQDLKYISPETMVALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVNLPLERDAESFLLKSPIAPCSLDKRVILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQDYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CDC25C-Ser216
Cancer Intensity
BRCA 0.236
COAD
HGSC
ccRCC
GBM 0.481
HNSC 0.035
LUAD -0.999
LUSC -1.233
non_ccRCC
PDAC
UCEC 1.48

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: